Mid-afternoon market update: Dow edges higher; Sequential brands shares spike higher
|Toward the end of trading Wednesday, the Dow traded up 0.08% to 29,846.44 while the NASDAQ fell 0.09% to 12,343.79. The S&P also rose, gaining 0.13% to 3,667.11.
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 13,726,300 cases with around 270,690 deaths. India confirmed a total of at least 9,499,410 confirmed cases and 138,120 deaths, while Brazil reported over 6,386,780 COVID-19 cases with 173,810 deaths. In total, there were at least 63,995,700 cases of COVID-19 worldwide with over 1,483,220 deaths, according to data compiled by Johns Hopkins University.
Leading and Lagging Sectors
Energy shares climbed 3.6% on Wednesday. Meanwhile, top gainers in the sector included Energy Fuels Inc. UUUU 13.6%, up 14%, and Kosmos Energy Ltd. KOS 14.42%, up 12%.
In trading on Wednesday, materials shares fell 1.3%.
Top Headline
Pfizer Inc PFE 3.03% and its German partner BioNTech SE BNTX 5.6% said Wednesday they have received regulatory approval in the United Kingdom for their COVID-19 vaccine..
The go-ahead from the Medicines and Healthcare Products Regulatory Agency (MHRA) means the U.K. has become the first country to approve a COVID-19 vaccine on an emergency basis ahead of the United States and the European Union.
Equities Trading UP
Sequential Brands Group, Inc. SQBG 25.03% shares shot up 24% to $11.69 after the company announced relaunch of broad review of strategic alternatives.
Shares of Tredegar Corporation TG 32.23% got a boost, shooting 31% to $21.66 after the company declared a special dividend of $5.97 per share.
Kingsway Financial Services Inc. KFS 30.52% shares were also up, gaining 24% to $3.7668 Kingsway Financial Services reported the closing of its acquisition of PWI Holdings, Inc.
Equities Trading DOWN
Ovid Therapeutics Inc. OVID 55.49% shares tumbled 55% to $2.9650 after the company announced topline results from the Phase 3 NEPTUNE study of OV101 for the treatment of Angelman syndrome, showing the study did not meet the primary endpoint of change in overall score on the Clinical Global Impression-Improvement-Angelman syndrome. Citigroup downgraded Ovid Therapeutics from Buy to Neutral and lowered the price target from$10 to $4.
Shares of Auris Medical Holding Ltd. EARS 34.16% were down 35% to $3.41 after the company priced an $8 million offering at $4 per share.
ReneSola Ltd SOL 21.46% was down, falling 21% to $6.24 after the company reported downbeat quarterly sales..
Commodities
In commodity news, oil traded up 1.7% to $45.29, while gold traded up 0.7% to $1,831.70.
Silver traded up 0.1% Wednesday to $24.095 while copper rose 0.1% to $3.4905.
Euro zone
European shares closed mixed today. The eurozone’s STOXX 600 fell 0.05%, the Spanish Ibex Index rose 0.98%, while Italy’s FTSE MIB Index declined 0.58%. Meanwhile, the German DAX 30 declined 0.52%, French CAC 40 rose 0.02% and London’s FTSE 100 gained 1.23%.
Retail sales in Germany climbed 2.6% in October versus a revised 1.9% decline in September.
Economics
US private sector created 307,000 jobs in November, the ADP reported. However, analysts were expecting an addition of 410,000 jobs.
US crude-oil inventories declined 700,000 barrels last week, the Energy Information Administration said.
The Federal Open Market Committee released its latest Beige Book report.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.